Please login to the form below

Not currently logged in
Email:
Password:

Kirsti Gjellan swaps Pfizer for Sobi

Takes up role as senior VP manufacturing operations at Swedish Orphan Biovitrum

Sobi Kirsti GjellanSwedish Orphan Biovitrum (Sobi) has appointed Pfizer's Kirsti Gjellan as senior VP manufacturing operations.

Sobi gains an experienced mind with Gjellan, who most recently serving as managing director for Pfizer in Sweden as well as site leader for its plant in Strängnäs.

The site opened in 2009 to produce the active ingredients for growth hormone Genotropin (somatropin) and the acromegaly treatment Somavert (pegvisomant).

Gjellan spent nine years at Pfizer in total, during which time she received the John Mitchell Quality Award for quality in manufacturing in 2006 and the Swedish Change Management Award for the best Change Management Project in 2013.

Her previous experience includes a 16-year period at AstraZeneca where she worked across drug discovery, research and manufacturing.

Geoffrey McDonough, president and CEO at Sobi, said he was “delighted” to welcome Gjellan to the company.

"Kirsti will continue to build on the legacy of our biologics manufacturing organisation, and to prepare us for our future products for patients with rare diseases.

Gjellan will complete her move to Sobi in September this year when current senior VP manufacturing operations Lena Nyström is due to retire.

28th May 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics